IMMURON (IMRN) vs Senti Biosciences, Inc. (SNTI)

IMMURON and Senti Biosciences, Inc. are both Biotechnology companies. IMMURON and Senti Biosciences, Inc. are of similar size ($10.0M and $9.6M). IMMURON grew revenue faster over the last twelve months: −6.62% against −70.7%. IMMURON has the higher net margin (−262.7% vs −3,789.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, IMMURON leads on 10 and Senti Biosciences, Inc. on 3.

Valuation

Metric IMRN SNTI Biotechnology median
P/E n/m n/m 7.88
P/S n/m 7.86 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.93 n/m 0.74
EV/Sales (3.50) 2.94 10.73
Earnings yield (1.75%) (536.36%) (28.84%)
Free cash flow yield 0.00% (369.11%) (23.03%)

Profitability

Metric IMRN SNTI Biotechnology median
Gross margin 71.28% 100.00% 65.16%
Operating margin 0.00% (4,181.12%) 0.00%
Net margin (262.71%) (3,789.30%) 0.00%
Free cash flow margin 0.00% (2,900.38%) 0.00%
Return on equity 0.00% (466.46%) (57.72%)
Return on assets 0.00% (97.52%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMRN SNTI Biotechnology median
Revenue growth (TTM) (6.62%) (70.73%) 5.64%
EPS growth (last fiscal year) 37.29% 77.31% —
Revenue growth, 5-year CAGR 116.96% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMRN SNTI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.17 0.83 4.73
Net debt to EBITDA 2.25 0.25 0.96

Dividend

Metric IMRN SNTI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IMRN SNTI Biotechnology median
Market cap 9.60m 9.96m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack